Indoco Remedies Limited has secured the European Health Authorities’ Certificate of EU Good Manufacturing Practices (GMP) Compliance for its sterile drug product manufacturing facility, Goa Plant II, located in Verna Industrial Estate, South Goa. This certification confirms that the facility meets the strict EU GMP standards for pharmaceutical production.
Aditi Panandikar, Managing Director of Indoco Remedies, expressed pride in the achievement, highlighting it as recognition of the company’s ongoing dedication to delivering high-quality, affordable medicines worldwide. She emphasized the company’s commitment to maintaining current GMP standards and consistently supplying reliable products to patients and customers.
Indoco Remedies is a fully integrated pharmaceutical company with a research-driven approach and a strong global footprint. With revenues of approximately US$180 million and a workforce exceeding 6,000, including over 400 scientists and field personnel, the company operates 11 manufacturing plants—7 dedicated to finished dosage forms and 4 to active pharmaceutical ingredients. Their facilities have received approvals from major regulatory bodies such as the USFDA and UK-MHRA.
The company produces a broad portfolio of pharmaceutical products catering to both domestic and international markets, with over 106 million prescriptions annually from a network of more than 240,000 doctors. Indoco’s domestic marketing divisions cover numerous therapeutic areas, including gastro-intestinal, respiratory, anti-infectives, ophthalmic, nutritionals, cardiovascular, anti-diabetics, pain management, and gynecology.
Some of Indoco’s flagship brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, and Glychek, among others. Internationally, the company partners with major generic pharmaceutical firms to expand its global reach.
